Toll Free: 1-888-928-9744

Pharmaxis Limited - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 46 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Pharmaxis Limited - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Pharmaxis Limited - Product Pipeline Review - 2014', provides an overview of the Pharmaxis Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pharmaxis Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Pharmaxis Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Pharmaxis Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Pharmaxis Limited's pipeline products

Reasons to buy

- Evaluate Pharmaxis Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Pharmaxis Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Pharmaxis Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Pharmaxis Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pharmaxis Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Pharmaxis Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Pharmaxis Limited Snapshot 5
Pharmaxis Limited Overview 5
Key Information 5
Key Facts 5
Pharmaxis Limited - Research and Development Overview 6
Key Therapeutic Areas 6
Pharmaxis Limited - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pharmaxis Limited - Pipeline Products Glance 11
Pharmaxis Limited - Late Stage Pipeline Products 11
Filing rejected/Withdrawn Products/Combination Treatment Modalities 11
Pharmaxis Limited - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Pharmaxis Limited - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Pharmaxis Limited - Drug Profiles 16
mannitol 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
ASM-8 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
PXS-25 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
PXS-64 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
PXS-2200 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
PXS-4159 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
PXS-4206 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
PXS-4681A 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
PXS-4728A 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
PXSTPI-1100 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecules to Inhibit LOXL2 for Oncology and Fibrosis 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
PXS-4820 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
PXS-5033-A 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Pharmaxis Limited - Pipeline Analysis 32
Pharmaxis Limited - Pipeline Products by Target 32
Pharmaxis Limited - Pipeline Products by Route of Administration 34
Pharmaxis Limited - Pipeline Products by Molecule Type 35
Pharmaxis Limited - Pipeline Products by Mechanism of Action 36
Pharmaxis Limited - Recent Pipeline Updates 38
Pharmaxis Limited - Dormant Projects 43
Pharmaxis Limited - Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46
List of Tables
Pharmaxis Limited, Key Information 5
Pharmaxis Limited, Key Facts 5
Pharmaxis Limited - Pipeline by Indication, 2014 8
Pharmaxis Limited - Pipeline by Stage of Development, 2014 9
Pharmaxis Limited - Monotherapy Products in Pipeline, 2014 10
Pharmaxis Limited - Filing rejected/Withdrawn, 2014 11
Pharmaxis Limited - Phase II, 2014 12
Pharmaxis Limited - Phase I, 2014 13
Pharmaxis Limited - Preclinical, 2014 14
Pharmaxis Limited - Discovery, 2014 15
Pharmaxis Limited - Pipeline by Target, 2014 33
Pharmaxis Limited - Pipeline by Route of Administration, 2014 34
Pharmaxis Limited - Pipeline by Molecule Type, 2014 35
Pharmaxis Limited - Pipeline Products by Mechanism of Action, 2014 37
Pharmaxis Limited - Recent Pipeline Updates, 2014 38
Pharmaxis Limited - Dormant Developmental Projects,2014 43
Pharmaxis Limited, Subsidiaries 44 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify